The Cornell University spinout will look at inhibitor drugs that could better fight autoimmune and inflammatory diseases.
Allied-Bristol Life Sciences, a biopharmaceutical partnership between commercialisation firm Allied Minds and pharmaceutical firm Bristol-Myers Squibb Company, yesterday established ABLS IV, a US-based autoimmune diseases treatment developer.
ABLS IV is based on research licensed from Cornell University to develop drugs to help tackle proteins known for causing a reaction during autoimmune diseases such as lupus, and through inflammation diseases like rheumatoid arthritis.
The approach furthers research from by Gang Lin, an associate research professor of microbiology and immunology in the university’s medical school., Weill Cornell Medicine, and Carl Nathan, chairman of the Department of Microbiology and Immunology.
Both will work as consultants to the business, which will collaborate with Weill Cornell Medicine and conduct a feasibility study prior to development.
Allied-Bristol Life Sciences was formed in 2014 to drive pre-clinical stage biopharmaceutical research by combining Allied Minds commercialisation expertise with Bristol-Myers Squibb’s drug discovery catalogue.
Satish Jindal, CEO of Allied-Bristol Life Sciences, said: “We are excited to enter feasibility studies for this novel class of selective immunoproteasome inhibitors, which has the potential to markedly improve treatments of a range of widely prevalent autoimmune and inflammatory diseases.”
